Author's response to reviews

Title: Chk1 Inhibition as a Novel Therapeutic Strategy for Treating Triple-Negative Breast and Ovarian Cancers

Authors:

Christopher Bryant (C.J.Bryant@bath.ac.uk)
Rebecca Rawlinson (rebecca.rawlinson@bath.edu)
Andrew J Massey (a.massey@veralis.com)

Version: 5 Date: 16 July 2014

Author's response to reviews: see over
MS: 1910808711284995

Chk1 Inhibition as a Novel Therapeutic Strategy for Treating Triple-Negative Breast and Ovarian Cancers Christopher Bryant, Rebecca Rawlinson and Andrew J Massey

Please find below our response to the Associate Editor’s comments:

1. PF-477736 and AZD7762 were purchased from Selleckchem and Axon Medchem respectively. We have added the following to the materials and methods section:

Compounds.
V158411 was synthesized according to the method described in [30] and prepared as a 20mM DMSO stock in DMSO. Solid stocks were purchased from the indicated suppliers and prepared as concentrated stock solutions in the appropriate solvent: gemcitabine (Apin Chemicals Inc), 20mM in H2O; cisplatin (Selleckchem), 3.33mM in 1% NaCl in H2O; oxaliplatin (Tocris), 5mM in H2O; carboplatin (Tocris), 25mM in H2O; PF-477736 (Selleckchem), 20mM in DMSO and AZD7762 (Axon Medchem), 20mM in DMSO.

We have updated the competing interests to make this a little clearer. AJM was joint program leader for the Vernalis Chk1 inhibitor discovery program and has already declared financial interests (salary and share options) in Vernalis.

Competing interests
CB, RR and AJM undertook this work as employees of Vernalis R&D Ltd. AJM is a stock option holder of Vernalis R&D Ltd. This work forms part of the Vernalis Chk1 inhibitor discovery and development program which is actively supported by Vernalis Ltd.